News

Approximately 88 subjects with documented hereditary angioedema (HAE) were screened and enrolled in an acute treatment open-label protocol. Subjects were eligible to receive open-label injections of Cinryze for

Wayne Badovinus, president and CEO of Mannatech, said: “We are appreciative of Terry’s many valuable contributions to the company. The board of directors, management and I personally extend

This approval enables the company to proceed with Phase I clinical trials in humans for its asthma drug candidate, Excellair. The investigational new drug (IND) review included ZaBeCor’s

The collaboration will deploy Ensemble Discovery’s proprietary diagnostic assays in human clinical studies to analyze combinations of epidermal growth factor receptors (EGFR) present in cancer tissues. This family

A total of 67 patients and controls in this multi-center US study consisting of 92% of eligible patients were followed for an average of 59 weeks after a

Mr Connaghan replaces Chuck Piccirillo, etrials’s vice president of technology, who has served as interim president and CEO since July 10, 2008. Mr Piccirillo will resume his position

Convivia is Raptor’s proprietary oral formulation of 4-methylpyrazole (4-MP) designed to reduce systemic acetaldehyde exposure and related symptoms in aldehyde dehydrogenase (ALDH2) deficient persons following alcohol consumption. Conducted

Dr Young will serve in a part-time capacity in addition to his current appointment as professor of medicine and director of the cardiovascular innovations program at the Ohio

Mr Keiser’s responsibilities will be distributed among current members of Alexion’s senior management reporting to Leonard Bell, CEO of Alexion. Mr Keiser will remain on Alexion’s board of